{"success":true,"data":{"pressRelease":{"id":"158337","rtpr_id":"nGNE4T3XvF-20261001","ticker":"NSISB","exchange":"Nasdaq Copenhagen","all_tickers":["NSISB"],"title":"Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities","author":"Globe Newswire","published_at":"2026-10-01T13:11:35.056Z","article_body":"Novonesis completes acquisition of MicroBioGen, strengthening its yeast\ncapabilities\n\nThe acquisition adds advanced yeast-breeding expertise with a proven track\nrecord in bioethanol and broader potential across industries.\n\nCOPENHAGEN, Denmark, October 1 – Novonesis today announced the completion of\nits acquisition of MicroBioGen, an Australian biotechnology company with\nleading scientific expertise in yeast strains for industrial applications and\na proven track record in bioethanol. All regulatory approvals have been\nobtained, and the transaction has closed.\n\nThe acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and\nits existing 23% ownership stake, further strengthening a collaboration that\nhas spanned more than a decade.\n\n“With this acquisition, we strengthen our yeast and R&D expertise and take\nanother step toward delivering on our 2030 strategy. We are pleased to welcome\nour new colleagues to Novonesis and bring these capabilities into our company,\nwhere we can unlock its broader potential. The acquisition reflects our\ndisciplined approach to investing for growth,” says Ester Baiget, CEO of\nNovonesis.\n\nAs a pure-play biology company, Novonesis draws on deep expertise in\nmicrobiology and industrial fermentation. MicroBioGen’s advanced\nyeast-breeding capabilities complement this scientific foundation, creating\nopportunities to develop new biosolutions for customers across multiple\nindustries.\n\n“MicroBioGen has been a highly valued partner for more than a decade, and\ntoday marks the next step in that journey. By bringing together our\ncomplementary expertise and technologies, we can further strengthen our yeast\ncapabilities and continue developing the biosolutions our customers need. We\nsee potential for applications not only in bioethanol but also across other\nindustries we serve, as is the case with many of our technologies,” says\nClaus Crone Fuglsang, Chief Scientific Officer at Novonesis.\n\nNovonesis will continue to support MicroBioGen's existing partners and ensure\ncontinuity in its collaborations.\n\nGet in touch\n\nMedia relations\n\nBenjamin Hjorth\nSenior Press Manager\nmedia-relations@novonesis.com+45 30 77 13 12","article_body_html":"","raw_payload":{"data":{"id":"nGNE4T3XvF-20261001","title":"Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities","author":"Globe Newswire","ticker":"NSISB","created":"2026-10-01T13:11:35.056Z","tickers":["NSISB"],"exchange":"Nasdaq Copenhagen","article_body":"Novonesis completes acquisition of MicroBioGen, strengthening its yeast\ncapabilities\n\nThe acquisition adds advanced yeast-breeding expertise with a proven track\nrecord in bioethanol and broader potential across industries.\n\nCOPENHAGEN, Denmark, October 1 – Novonesis today announced the completion of\nits acquisition of MicroBioGen, an Australian biotechnology company with\nleading scientific expertise in yeast strains for industrial applications and\na proven track record in bioethanol. All regulatory approvals have been\nobtained, and the transaction has closed.\n\nThe acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and\nits existing 23% ownership stake, further strengthening a collaboration that\nhas spanned more than a decade.\n\n“With this acquisition, we strengthen our yeast and R&D expertise and take\nanother step toward delivering on our 2030 strategy. We are pleased to welcome\nour new colleagues to Novonesis and bring these capabilities into our company,\nwhere we can unlock its broader potential. The acquisition reflects our\ndisciplined approach to investing for growth,” says Ester Baiget, CEO of\nNovonesis.\n\nAs a pure-play biology company, Novonesis draws on deep expertise in\nmicrobiology and industrial fermentation. MicroBioGen’s advanced\nyeast-breeding capabilities complement this scientific foundation, creating\nopportunities to develop new biosolutions for customers across multiple\nindustries.\n\n“MicroBioGen has been a highly valued partner for more than a decade, and\ntoday marks the next step in that journey. By bringing together our\ncomplementary expertise and technologies, we can further strengthen our yeast\ncapabilities and continue developing the biosolutions our customers need. We\nsee potential for applications not only in bioethanol but also across other\nindustries we serve, as is the case with many of our technologies,” says\nClaus Crone Fuglsang, Chief Scientific Officer at Novonesis.\n\nNovonesis will continue to support MicroBioGen's existing partners and ensure\ncontinuity in its collaborations.\n\nGet in touch\n\nMedia relations\n\nBenjamin Hjorth\nSenior Press Manager\nmedia-relations@novonesis.com+45 30 77 13 12"},"type":"article","timestamp":"2026-10-01T13:11:35.164146979Z","server_sent_at_ms":1790860295164},"received_at":"2026-10-01T13:11:35.215Z","source_url":null},"analysis":{"id":"146970","press_release_id":"158337","analysis_json":{"industry":{"label":"Chemicals","sector":"Materials"},"redFlags":[],"eventType":"m_and_a","narrative":"Novonesis has completed its acquisition of MicroBioGen, an Australian biotechnology company specializing in yeast strains for industrial applications and bioethanol.\n\nAll regulatory approvals were obtained and the transaction has closed; Novonesis previously invested in MicroBioGen in 2013 and held a 23% ownership stake.\n\nManagement frames the deal as strengthening yeast and R&D capabilities in support of its 2030 strategy, with potential applications beyond bioethanol across industries Novonesis serves.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Disciplined bolt-on of a decade-long partner deepens Novonesis' industrial yeast and biosolutions platform."},"keyFigures":{"customDimensions":{"prior_ownership_stake":"23%"}},"quotedText":"With this acquisition, we strengthen our yeast and R&D expertise and take another step toward delivering on our 2030 strategy.","namedEntities":{"people":[{"name":"Ester Baiget","role":"CEO of Novonesis"},{"name":"Claus Crone Fuglsang","role":"Chief Scientific Officer at Novonesis"},{"name":"Benjamin Hjorth","role":"Senior Press Manager, Media Relations"}],"products":[],"companies":[{"name":"Novonesis","ticker":"NSISB","relationship":"acquirer"},{"name":"MicroBioGen","relationship":"target"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Completed bolt-on acquisition of an existing 23%-owned partner, adding yeast-breeding capabilities; strategic but small-scale tuck-in with no deal value or earnings impact disclosed."},"tickerRelevance":{"others":[],"primary":"NSISB"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap foreign issuer","eventGravity":"completed bolt-on acquisition, no deal value disclosed","sectorWeight":"industrial biotech/biosolutions","householdBrandBoost":0}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Novonesis has completed its acquisition of MicroBioGen, an Australian biotechnology company specializing in yeast strains for industrial applications and bioethanol.\n\nAll regulatory approvals were obtained and the transaction has closed; Novonesis previously invested in MicroBioGen in 2013 and held a 23% ownership stake.\n\nManagement frames the deal as strengthening yeast and R&D capabilities in support of its 2030 strategy, with potential applications beyond bioethanol across industries Novonesis serves.","key_figures":{"customDimensions":{"prior_ownership_stake":"23%"}},"named_entities":{"people":[{"name":"Ester Baiget","role":"CEO of Novonesis"},{"name":"Claus Crone Fuglsang","role":"Chief Scientific Officer at Novonesis"},{"name":"Benjamin Hjorth","role":"Senior Press Manager, Media Relations"}],"products":[],"companies":[{"name":"Novonesis","ticker":"NSISB","relationship":"acquirer"},{"name":"MicroBioGen","relationship":"target"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T13:11:39.696Z","global_importance":30,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap foreign issuer","eventGravity":"completed bolt-on acquisition, no deal value disclosed","sectorWeight":"industrial biotech/biosolutions","householdBrandBoost":0}},"durationMs":4494,"modelName":"glm-5.3-flashx"}}